News >

Goy Reflects on MCL Data Presented at ASH 2017

Angelica Welch
Published: Wednesday, Dec 13, 2017

The mechanism of resistance of CAR T cells is something that we are starting to hear. This is the rationale for a trial we are about to start called ZUMA-6, which is ongoing and looking at axicabtagene ciloleucel (axi-cel; Yescarta) plus atezolizumab (Tecentriq). It is a really exciting time to be at the 2017 ASH Annual Meeting.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x